Listed

Citius Oncology, Inc.: Form 10-Q for the period ended Sep 30, 2023

Filed with the SEC on Nov 20, 2023 and accepted by EDGAR at Nov 20, 2023, 17:25 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income3 months2023-07-01 to 2023-09-30−$421.5kus-gaap:OperatingIncomeLoss
Operating income9 months2023-01-01 to 2023-09-30−$768.9kus-gaap:OperatingIncomeLoss
Net income3 months2023-07-01 to 2023-09-30$157.9kus-gaap:NetIncomeLoss
Net income9 months2023-01-01 to 2023-09-30$1.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-07-01 to 2023-09-30$0.02us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2023-01-01 to 2023-09-30$0.15us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-07-01 to 2023-09-30$0.02us-gaap:EarningsPerShareBasic
Basic EPS9 months2023-01-01 to 2023-09-30$0.15us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-07-01 to 2023-09-306,600,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2023-01-01 to 2023-09-306,600,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2023-01-01 to 2023-09-30−$382.5kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2023-09-30$26.5kus-gaap:Cash
Current assetsAt period end2023-09-30$85.2kus-gaap:AssetsCurrent
Total assetsAt period end2023-09-30$70.7mus-gaap:Assets
Current liabilitiesAt period end2023-09-30$1.2mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2023-09-30−$1.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-23-042170. Last ingested by Listed: Nov 4, 2026, 17:46 ET. Listed shows no prices and gives no investment advice.